98
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Comprehensive Analysis to Identify Enhancer-Regulated Inflammation-Associated Genes in Lung Adenocarcinoma

, & ORCID Icon
Pages 7115-7129 | Published online: 11 Sep 2021

References

  • BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
  • TravisWD, BrambillaE, NicholsonAG, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260. doi:10.1097/JTO.000000000000063026291008
  • SiegelRL, MillerKD, JemalA. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.2125425559415
  • MantovaniA, AllavenaP, SicaA, BalkwillF. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature0720518650914
  • ShojiF, KozumaY, ToyokawaG, YamazakiK, TakeoS. Complete blood cell count-derived inflammatory biomarkers in early-stage non-small-cell lung cancer. Ann Thorac Cardiovasc Surg. 2020;26(5):248–255. doi:10.5761/atcs.oa.19-0031532074540
  • TaniguchiK, KarinM. NF-kappaB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309–324.29379212
  • OshiM, NewmanS, TokumaruY, et al. Inflammation is associated with worse outcome in the whole cohort but with better outcome in triple-negative subtype of breast cancer patients. J Immunol Res. 2020;2020:5618786. doi:10.1155/2020/561878633457427
  • CaragliaM, DicitoreA, MarraM, et al. Type I interferons: ancient peptides with still under-discovered anti-cancer properties. Protein Pept Lett. 2013;20(4):412–423.23016588
  • BatlleE, MassagueJ. Transforming growth factor-beta signaling in immunity and cancer. Immunity. 2019;50(4):924–940. doi:10.1016/j.immuni.2019.03.02430995507
  • TomitaM, AyabeT, NakamuraK. The advanced lung cancer inflammation index is an independent prognostic factor after surgical resection in patients with non-small-cell lung cancer. Interact Cardiovasc Thorac Surg. 2018;26(2):288–292. doi:10.1093/icvts/ivx32929049691
  • KobayashiS, KarubeY, InoueT, et al. Advanced lung cancer inflammation index predicts outcomes of patients with pathological stage IA lung adenocarcinoma following surgical resection. Ann Thorac Cardiovasc Surg. 2019;25(2):87–94. doi:10.5761/atcs.oa.18-0015830333361
  • HuZ, WuW, ZhangX, et al. Advanced lung cancer inflammation index is a prognostic factor of patients with small-cell lung cancer following surgical resection. Cancer Manag Res. 2021;13:2047–2055. doi:10.2147/CMAR.S29595233664592
  • BachaS, SghaierA, HabibechS, et al. Advanced lung cancer inflammation index: a prognostic score in patients with metastatic non-small cell lung cancer. Tunis Med. 2017;95(11):976–981.29877556
  • TomczakK, CzerwinskaP, WiznerowiczM. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol. 2015;19(1A):A68–77.
  • WeinsteinJN, CollissonEA, MillsGB, et al.; Cancer Genome Atlas Research, N. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):1113–1120. doi:10.1038/ng.276424071849
  • LiuJ, LiR, LiaoX, HuB, YuJ. Comprehensive investigation of the clinical significance and molecular mechanisms of plasmacytoma variant translocation 1 in sarcoma using genome-wide RNA sequencing data. J Cancer. 2019;10(20):4961–4977. doi:10.7150/jca.3167531598169
  • XieL, SongX, LinH, et al. Aberrant activation of CYR61 enhancers in colorectal cancer development. J Exp Clin Cancer Res. 2019;38(1):213. doi:10.1186/s13046-019-1217-931118064
  • SpitzF, FurlongEE. Transcription factors: from enhancer binding to developmental control. Nat Rev Genet. 2012;13(9):613–626. doi:10.1038/nrg320722868264
  • CaloE, WysockaJ. Modification of enhancer chromatin: what, how, and why?Mol Cell. 2013;49(5):825–837. doi:10.1016/j.molcel.2013.01.03823473601
  • SurI, TaipaleJ. The role of enhancers in cancer. Nat Rev Cancer. 2016;16(8):483–493. doi:10.1038/nrc.2016.6227364481
  • HerzHM. Enhancer deregulation in cancer and other diseases. Bioessays. 2016;38(10):1003–1015. doi:10.1002/bies.20160010627570183
  • RitchieME, PhipsonB, WuD, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.25605792
  • HanzelmannS, CasteloR, GuinneyJ. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14(1):7. doi:10.1186/1471-2105-14-7
  • NewmanAM, LiuCL, GreenMR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.333725822800
  • SubramanianA, TamayoP, MoothaVK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550. doi:10.1073/pnas.050658010216199517
  • DiakosCI, CharlesKA, McMillanDC, ClarkeSJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–e503. doi:10.1016/S1470-2045(14)70263-325281468
  • SalgadoR, DenkertC, DemariaS, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2015;26(2):259–271. doi:10.1093/annonc/mdu45025214542
  • Gomez-LarrauriA, OuroA, TruebaM, Gomez-MunozA. Regulation of cell growth, survival and migration by ceramide 1-phosphate - implications in lung cancer progression and inflammation. Cell Signal. 2021;83:109980. doi:10.1016/j.cellsig.2021.10998033727076
  • MerloA, Dalla SantaS, DolcettiR, ZanovelloP, RosatoA. Reverse immunoediting: when immunity is edited by antigen. Immunol Lett. 2016;175:16–20.27131431
  • LiB, CuiY, DiehnM, LiR. Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol. 2017;3(11):1529–1537. doi:10.1001/jamaoncol.2017.160928687838
  • MaQ, XuY, LiaoH, et al. Identification and validation of key genes associated with non-small-cell lung cancer. J Cell Physiol. 2019;234(12):22742–22752. doi:10.1002/jcp.2883931127628
  • JiaQ, ChenS, TanY, LiY, TangF. Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms. Exp Mol Med. 2020;52(5):713–723. doi:10.1038/s12276-020-0428-732382065
  • LohC, ParkSH, LeeA, YuanR, IvashkivLB, KallioliasGD. TNF-induced inflammatory genes escape repression in fibroblast-like synoviocytes: transcriptomic and epigenomic analysis. Ann Rheum Dis. 2019;78(9):1205–1214. doi:10.1136/annrheumdis-2018-21478331097419
  • CieslikM, HoangSA, BaranovaN, et al. Epigenetic coordination of signaling pathways during the epithelial-mesenchymal transition. Epigenetics Chromatin. 2013;6(1):28. doi:10.1186/1756-8935-6-2824004852
  • ZhouT, YuL, HuangJ, et al. GDF10 inhibits proliferation and epithelial-mesenchymal transition in triple-negative breast cancer via upregulation of Smad7. Aging. 2019;11(10):3298–3314. doi:10.18632/aging.10198331147529
  • ChengCW, HsiaoJR, FanCC, et al. Loss of GDF10/BMP3b as a prognostic marker collaborates with TGFBR3 to enhance chemotherapy resistance and epithelial-mesenchymal transition in oral squamous cell carcinoma. Mol Carcinog. 2016;55(5):499–513. doi:10.1002/mc.2229725728212
  • DaiZ, PopkieAP, ZhuWG, et al. Bone morphogenetic protein 3B silencing in non-small-cell lung cancer. Oncogene. 2004;23(20):3521–3529. doi:10.1038/sj.onc.120744115116090
  • WangJJ, MakOT. Induction of apoptosis in non-small cell lung carcinoma A549 cells by PGD(2) metabolite, 15d-PGJ(2). Cell Biol Int. 2011;35(11):1089–1096. doi:10.1042/CBI2010070721999315
  • CuiY, LiangS, ZhangS, et al. ABCA8 is regulated by miR-374b-5p and inhibits proliferation and metastasis of hepatocellular carcinoma through the ERK/ZEB1 pathway. J Exp Clin Cancer Res. 2020;39(1):90. doi:10.1186/s13046-020-01591-132430024
  • GuoY, WangZW, SuWH, ChenJ, WangYL. Prognostic value and immune infiltrates of ABCA8 and FABP4 in stomach adenocarcinoma. Biomed Res Int. 2020;2020:4145164. doi:10.1155/2020/414516432685482
  • DemidenkoR, RazanauskasD, DaniunaiteK, LazutkaJR, JankeviciusF, JarmalaiteS. Frequent down-regulation of ABC transporter genes in prostate cancer. BMC Cancer. 2015;15(1):683. doi:10.1186/s12885-015-1689-826459268
  • DunnJR, PanutsopulosD, ShawMW, et al. METH-2 silencing and promoter hypermethylation in NSCLC. Br J Cancer. 2004;91(6):1149–1154. doi:10.1038/sj.bjc.660210715328519
  • ZhangY, HeRQ, DangYW, et al. Comprehensive analysis of the long noncoding RNA HOXA11-AS gene interaction regulatory network in NSCLC cells. Cancer Cell Int. 2016;16(1):89. doi:10.1186/s12935-016-0366-627980454